Elasmogen’s CEO Dr Caroline Barelle has been named in Labiotech.eu’s list of top female entrepreneurs. Read the article here.
Year: 2017
Feldan Therapeutics and Elasmogen Announce Research Agreement with Amgen to Develop Intracellular Biologics | 09.05.2017
Combined Feldan Shuttle and Elasmogen soloMER technology will be used to deliver intracellular candidates for two targets Aberdeen, Scotland and Quebec City, Canada; 9 May 2017: Elasmogen Ltd, focused on the development of next generation biologics, and Feldan Therapeutics, focused on intracellular delivery of proteins, today announce a research collaboration with Amgen, to develop […]
Elasmogen receives £1.2 M in grant and equity investment | 16.03.2017
Funding from Deepbridge Capital, Innovate UK and Scottish Investment Bank will support development of next generation Ophthalmology biologics Thursday, 16 March 2017: Aberdeen, Scotland: Elasmogen Ltd, developer of soloMERTM biologics, today announced that it has received a Biomedical Catalyst Grant from the UK’s innovation agency, Innovate UK and matching investment from Deepbridge Capital and […]
Elasmogen Ltd – shark proteins for drug discovery | 20.01.2017
BBSRC support for research and commercialisation contributed to the creation of award-winning spin-out company Elasmogen by Dr Caroline Barelle and Professor Andrew Porter at the University of Aberdeen. The company is developing new medicines based on the discovery of certain antibody-like molecules found in sharks. IMPACT SUMMARY University of Aberdeen researchers Dr Caroline Barelle and […]